FDA approves Alcon's Simbrinza for glaucoma and ocular hypertension

04/22/2013 | RTT News

Novartis unit Alcon obtained approval from the FDA to market Simbrinza Suspension, a fixed-dose combination of Brinzolamide and Brimonidine Tartrate, for the reduction of elevated intraocular pressure in patients suffering from primary open-angle glaucoma or ocular hypertension. The approval makes Simbrinza the first fixed-dose glaucoma combo treatment in the U.S. that doesn't contain a beta blocker.

View Full Article in:

RTT News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT